(a) Quantitative PCR validation of 1q21.1 CNV states shows 100% agreement with SNP genotyping data. Box plot is shown for 0-copy (n=10), 1-copy (n=16), 2-copy (n=12), 3-copy (n=6) and > 3 copies (n=2). (b) FISH validation of 1q21.1 deletion. Shown are metaphase spreads from lymphoblastoid cell lines established from an individual with normal 2-copy (left) and an individual with hemizygous deletion (right). Red arrows: BAC RP4-790G17 which maps just outside of the deletion CNV from 148,424,830–148,557,655 (two copies in both individuals). Green arrows: fosmid W12-1967b11 which maps within the deleted region from 147,382,742–147,420,968, encompassing the first two exons of the putative NBPF transcript (one copy in individual with hemizygous deletion). (c) Box plot showing correlation between CNV state and NBPFX transcript levels demonstrated using real-time quantitative PCR in eighteen neuroblastoma samples: 1-copy (n=5), 2-copy (low, n=4), 2-copy (high, n=3), 3-copy (n=5), and > 3 copies (n=1). 2-copy samples clustered into two distinct groups consistent with expression difference based on whether copies are in “cis” (2:0 CNV genotype) or “trans” (1:1 CNV genotype); see text for details. (d) Expression of NBPFX in normal fetal and adult tissues using real-time quantitative reverse transcriptase PCR showed highest expression in fetal brain (13–22 wks) and fetal sympathetic ganglia samples (18–22 wks) which were collected at the Children’s Hospital of Philadelphia.